NICE technology appraisal guidance [TA253]
Published date:
April 2012

NICE recommends boceprevir with peginterferon alfa and ribavirin as a possible treatment for genotype 1 chronic hepatitis C in adults with the earlier stages of liver disease (known as compensated liver disease).

Who can have boceprevir?

You should be able to have boceprevir with peginterferon alfa and ribavirin if:

you have not been treated for genotype 1 chronic hepatitis C before or

you have been treated for genotype 1 chronic hepatitis C before but your treatment did not work.

Why has NICE said this?

NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE recommended boceprevir because it works better than other treatments available on the NHS. Although it also costs more than other treatments, this was justified by the benefits it provided.